A medical emergency in a gym class started Megann’s life-changing journey with epilepsy, including a sudden diagnosis and intense treatment plan. Discover Megann’s inspiring story, detailing her challenges with treatment, loss of independence and how she empowers herself and other to live life to the fullest.

Jesse was a senior in college studying to become a doctor when he was diagnosed with acute lymphoblastic leukemia (ALL). His studies in the medical field inspired him to ask critical questions and advocate for himself throughout his ALL journey. By combining this determination with a positive attitude, Jesse navigated one of the most challenging times of his life with resilience and hope.

Rachael was just 36 years old when she was diagnosed with breast cancer. Her decade long treatment journey has left its mark and worries for the future, but emerging out of the darkness is a cherished son she wasn’t sure if she could have, a powerful drive to help others on their cancer journeys and true perspective on what matters in life.

As we deepen our commitment to oncology, we’re focused on bringing forward meaningful innovation for patients, especially those facing rare and aggressive cancers like H3 K27M-mutant diffuse midline glioma. With the FDA approval of the first treatment for this cancer, there is new hope for patients and families who are navigating this life-threatening disease. 

H3 K27M-mutant diffuse midline glioma is a highly aggressive brain tumor most commonly found in children and young adults. Because of poor prognosis associated with this disease due to its deep location in the brain and aggressive biology, early identification and accurate molecular diagnosis are essential to help determine the best treatment course.

Scientific advances are reshaping how small cell lung cancer is understood and treated. As interest grows in first-line maintenance strategies, researchers are exploring new ways to extend the impact of initial therapy in this historically difficult-to-treat cancer.

Our teams at Jazz recognize the importance of collaborating with and learning from the sleep community. Our ongoing data generation is fueled by insights from people living with narcolepsy and idiopathic hypersomnia and expand our understanding of the realities of people living with these conditions.

We are focused on advancing innovation where it matters most for people facing some of the toughest cancers. Explore how our commitment to high-unmet need diseases like extensive-stage small cell lung cancer (ES-SCLC) is helping to drive meaningful progress in cancer care.

March 26^th marks Purple Day – a pivotal moment in time to recognize and support millions of people around the world who are living with epilepsy. We’re using this day to pause and reflect on the progress that has been made for people in the epilepsy community and advance our purpose to innovate to transform the lives of patients and their families.